Latest Articles
Merck's endometrial cancer therapy fails trial - Reuters
Merck's endometrial cancer therapy fails trial Reuters
Published: May 9, 2024, 7 a.m.
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer AJMC.com Managed Markets Network
Published: May 9, 2024, 7 a.m.
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma
Published: May 9, 2024, 7 a.m.
Merck's endometrial cancer therapy fails trial - ETHealthWorld
Merck's endometrial cancer therapy fails trial ETHealthWorld
Published: May 9, 2024, 7 a.m.
Cryotherapy For Abdominal Wall Endometriosis - François Cornelis, MD - Endometriosis Foundation of America - The Blossom
Cryotherapy For Abdominal Wall Endometriosis - François Cornelis, MD Endometriosis Foundation of America - The Blossom
Published: May 2, 2024, 7 a.m.
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate - Frontiers
Early GnRH-agonist therapy does not negatively impact the endometrial repair process or live birth rate Frontiers
Published: April 29, 2024, 7 a.m.
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer - Cancer Health Treatment News
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer Cancer Health Treatment News
Published: April 9, 2024, 7 a.m.
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response - Nature.com
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response Nature.com
Published: April 2, 2024, 7 a.m.
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post
Published: March 27, 2024, 6:45 p.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network
Published: March 21, 2024, 7 a.m.
Link copied to clipboard!